SAN FRANCISCO — A bacteria typically linked to periodontal disease, Fusobacterium nucleatum (F. nuc), could play an important role in the rising incidence of colorectal cancer in people under the age of 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly four-fold higher rate in people over 75 than in those under 45 years of age, pointing out how differences in the bacteria that comprise what is known as the body’s microbiome could affect cancer outcomes to varying degrees.
These are the preliminary findings of an ongoing study from researchers at Georgetown Lombardi Comprehensive Cancer Center that will be presented in a poster session at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco from January 23-25, 2020.
Colorectal cancer incidence has been declining for several decades in people over 55, in part because of the increased use of screening for the disease, particularly with colonoscopy which can find and remove polyps before they become cancerous. Such screenings are generally not recommended for people under age 50.
But colorectal cancer rates have been increasing at nearly a 2% annual rate in people under age 55 since 2006. There are many theories about why, including a rise in obesity, diabetes, and diets low in whole grains among younger people.
“We haven’t seen large genetic differences in colorectal tumors from younger versus older people, so we hypothesize that something else, perhaps the microbiome, is contributing to the rise in incidence of the disease in younger people,” said Benjamin Adam Weinberg, MD, an assistant professor of medicine at Georgetown Lombardi.
Scientists have known that certain microbes that comprise the microbiome, which consists of different types of bacteria, fungi and viruses, can disturb the lining of the colon and promote tissue inflammation. This can result in mutations to the DNA of cells in the colon and lead to cancer. Researchers also know that F. nuc can promote cancerous growth by suppressing immune responses in the colon.
To better understand the role of the microbime in colorectal cancer, Weinberg and colleagues looked at the DNA and microbiome of archived tumors, as well as adjacent normal tissue when available, from 31 patients with colorectal cancer who were diagnosed before the age of 45 or after the age of 65.
Overall, the investigators found 478 unique bacterial and fungal species in the tumors. One of the most common bacteria found was F. nuc, which appeared in five of the younger patients’ tumors and in three of the older patients’ tumors. The researchers also found a significant difference in the rate of Moraxella osloensis (11% vs. 46%) in younger compared to older patients.
“There was a much higher presence of F. nuc in younger patients than we expected,” said Dr. Weinberg. “As to whether this bacterium alone can explain some of the rise in incidence of colorectal cancer in younger people is something we need to explore, and to aid in that effort this ongoing study will incorporate tumors from up to a total of 144 people.”
In addition to Weinberg, authors include Hongkun Wang, Xue Geng, Emily Bakhshi, Krysta Chaldekas, Brent T. Harris, Dionyssia Clagett, John Marshall at Georgetown. An additional author is Shadi Shokralla from Clear Labs, Menlo Park, Calif.
This research was supported by the Colorectal Cancer Alliance and the Victoria Casey and Peter Teeley Foundation.
About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center is designated by the National Cancer Institute (NCI) as a comprehensive cancer center. A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington D.C. area. It serves as the research engine for MedStar Health, Georgetown University’s clinical partner. Georgetown Lombardi is also an NCI recognized consortium with John Theurer Cancer Center/Hackensack Meridian Health in Bergen County, New Jersey. The consortium reflects an integrated cancer research enterprise with scientists and physician-researchers from both locations. Georgetown Lombardi seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic, translational and clinical research, patient care, community education and outreach to service communities throughout the Washington region, while its consortium member John Theurer Cancer Center/Hackensack Meridian Health serves communities in northern New Jersey. Georgetown Lombardi is a member of the NCI Community Oncology Research Program (UG1CA239758). Georgetown Lombardi is supported in part by a National Cancer Institute Cancer Center Support Grant (P30CA051008). Connect with Georgetown Lombardi on Facebook (Facebook.com/GeorgetownLombardi) and Twitter (@LombardiCancer).
About Georgetown University Medical Center
Georgetown University Medical Center (GUMC) is an internationally recognized academic health and science center with a four-part mission of research, teaching, service and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis — or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health. Connect with GUMC on Facebook (Facebook.com/GUMCUpdate), Twitter (@gumedcenter).